Subacute neurological sequelae in mild
COVID-19 outpatients

NUMANOĞLU, NUMAN; POYRAZ, BARIS MUSTAFA; Canlar, Sule; Eroglu, Erdal; TASKIRAN SAG, Aslihan; Ozulken, Kemal; Mumcuoglu, Tarkan

doi:10.5578/tt.20229904

Subacute neurological sequelae in mild COVID-19 outpatients

Aslıhan TAŞKIRAN SAĞ, (TOBB ETÜ Tıp Fakültesi Hastanesi, Göz Hastalıkları Kliniği, Ankara, Türkiye)

Erdal EROĞLU, (TOBB ETÜ Tıp Fakültesi Hastanesi, Göz Hastalıkları Kliniği, Ankara, Türkiye)

Şule CANLAR, (TOBB ETÜ Tıp Fakültesi Hastanesi, Endokrinoloji ve Metabolizma Kliniği, Ankara, Türkiye)

Barış Mustafa POYRAZ, (TOBB ETÜ Tıp Fakültesi Hastanesi, Göğüs Hastalıkları Kliniği, Ankara, Türkiye)

Kemal ÖZÜLKEN, (TOBB ETÜ Tıp Fakültesi Hastanesi, Göz Hastalıkları Kliniği, Ankara, Türkiye)

Tarkan MUMCUOĞLU, (TOBB ETÜ Tıp Fakültesi Hastanesi, Göz Hastalıkları Kliniği, Ankara, Türkiye)

Numan NUMANOĞLU (TOBB ETÜ Tıp Fakültesi Hastanesi, Göğüs Hastalıkları Kliniği, Ankara, Türkiye)

Tüberküloz ve Toraks

8 5

Yıl: 2022 Cilt: 70 Sayı: 1 Sayfa Aralığı: 27 - 36 Metin Dili: İngilizce DOI: 10.5578/tt.20229904 İndeks Tarihi: 29-06-2022

Subacute neurological sequelae in mild COVID-19 outpatients

Öz:

Introduction: Neurological aspect of COVID-19 is less understood compared to its respiratory and systemic effects. We aimed to define subacute neurological sequelae in patients who recovered from mild COVID-19. Materials and Methods: This study enrolled long COVID patients who had mild infection, were non-hospitalized, and admitted to our hospital with neurological complaints occurring after COVID-19. The evaluation included detailed history of the symptoms, neurological examination, blood tests and necessary investigations relevant to their personal medical situation, and also a retrospective inquiry about their respiratory and neurological status during the acute phase of infection. Descriptive statistical measures, Chi-square and Student’s t-test were utilized. Results: We identified 50 patients (29F/21M) with a mean age of 36.9 ± 1.6 (mean ± SEM). The average time from COVID-19 to admission was 99 days(min-max= 15-247). Most frequent neurological complaints were headache (42%) and cognitive dysfunction (42%). Sleep disturbance (36%), prolonged anosmia (30%), prolonged ageusia (22%), fatigue (22%), and dizziness (8%) followed. Most patients with headache experienced headache also as an acute manifestation of COVID-19 (p= 0.02). Acute-stage sleep disorders were found to be more associated with subacute cognitive symptoms than other central symptoms (p= 0.008). The most common neurological symptom in the acute phase was headache (74%). Six patients, despite the absence of any acute-stage neurological symptoms, presented with emergence of subacute neurological sequela. There were only five patients with pulmonary involvement during the acute stage, who were not different from the rest of the cohort in terms of neurological sequelae. There was no increase of inflammatory markers in the blood tests at the subacute stage, or no association of the symptoms to biochemical parameters. Conclusion: This study gives a description of neurological sequelae of mild COVID-19 at the subacute stage, in a relatively young group, and reveals that cognitive disturbances, as well as headache, are quite frequent.

Anahtar Kelime:

Ayaktan hafif COVID-19 hastalarında subakut nörolojik sekeller

Öz:

Giriş: COVID-19’un nörolojik yönü, solunumsal ve sistemik etkilerine kıyasla daha az bilinmektedir. Bu çalışmada, hafif COVID-19 geçirmiş hastalarda subakut nörolojik sekelleri tanımlamayı amaçladık. Materyal ve Metod: Çalışmaya hafif COVID-19 geçirmiş, hastaneye yatırılmadan izlenmiş ve sonrasında nörolojik şikayetlerle bize başvuran uzun COVID hastaları alındı. Değerlendirme sırasında semptomların ayrıntılı anamnezi alındı, nörolojik muayene yapıldı; kan testleri ve kendi tıbbi durumlarıyla ilgili gereken araştırmalar, ayrıca enfeksiyonun akut fazı sırasında respiratuvar ve nörolojik durumlarına yönelik geriye dönük bir sorgulama yapıldı. Tanımlayıcı istatistiksel parametreler, Ki-kare ve Student t-testi kullanıldı. Bulgular: Ortalama yaşı 36.9 ± 1.6 (ortalama ± SH) olan 50 hasta (29K/21E) tespit edildi. COVID-19’dan kabule kadar geçen ortalama süre 99 gündü (min-maks= 15-247). En sık görülen nörolojik şikayetler baş ağrısı (%42) ve bilişsel işlev bozukluğu (%42) idi. Bunu uyku bozukluğu (%36), uzamış anozmi (%30), uzamış aguzi (%22), yorgunluk (%22) ve baş dönmesi (%8) izlemekteydi. Baş ağrısı olan hastaların çoğu, aynı zamanda COVID-19’un akut bir belirtisi olarak da baş ağrısını yaşamışlardı (p= 0.02). Diğer merkezi semptomlara göre akut dönemdeki uyku bozukluklarının subakut kognitif semptomlarla daha fazla ilişkili olduğu bulundu (p= 0.008). Akut dönemde en sık görülen nörolojik semptom baş ağrısıydı (%74). Altı hasta herhangi bir akut dönem nörolojik semptomu olmamasına rağmen subakut nörolojik sorun gelişimi ile başvurmuştu. Akut dönemde pulmoner tutulumu olan sadece beş hasta vardı ve nörolojik sekeller açısından kohortun geri kalanından farklılık göstermiyordu. Subakut aşamada kan testlerinde enflamatuvar belirteçlerde artış yoktu ve semptomların biyokimyasal parametrelerle ilişkisi tespit edilmedi. Sonuç: Bu çalışma, nispeten genç bir grupta subakut aşamada hafif COVID-19’un nörolojik sekellerinin bir tanımını vermekte ve baş ağrısının yanı sıra bilişsel bozuklukların oldukça sık olduğunu ortaya koymaktadır.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020; 92(6): 552-5. https://doi.org/10.1002/jmv.25728
2. Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol 2021; 23: 1-13. https://doi.org/10.1007/s00415-021-10406-y
3. Nordvig AS, Rimmer KT, Willey JZ, Thakur KT, Boehme AK, Vargas WS, et al. Potential neurological manifestations of COVID-19. Neurol Clin Prac 2021; 11(2): e135-e146. https://doi.org/10.1212/CPJ.0000000000000897
4. Wang L, Shen Y, Li M, Chuang H, Ye Y, Zhao H, et al. Clinical manifestations and evidence of neurological involvement in 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. J Neurol 2020; 267(10): 2777-89. https://doi.org/10.1007/s00415-020- 09974-2
5. Newcombe VFJ, Dangayach NS, Sonneville R. Neurological complications of COVID-19. Intensive Care Med 2021; 47: 1021-3. https://doi.org/10.1007/s00134-021-06439- 6
Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 2020; 77(8): 1018- 27. https://doi.org/10.1001/jamaneurol.2020.2065
7. Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar Hari M, Lachmann G, et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 2021; 9(6): 622- 42. https://doi.org/10.1016/S2213-2600(21)00218-6
8. Sridhar S, Nicholls J. Pathophysiology of infection with SARS-CoV-2-What is known and what remains a mystery. Respirology 2021; 26(7): 652-65. https://doi. org/10.1111/resp.14091
9. Garcia Monco JC, Cabrera Muras A, Erburu Iriarte M, Rodrigo Armenteros P, Collía Fernández A, Arranz Martínez J, et al. Neurological manifestations in a prospective unselected series of hospitalized COVID-19 patients. Neurol Clin Prac 2021; 11(2): e64-e72. https://doi. org/10.1212/CPJ.0000000000000913
10. Anand P, Zhou L, Bhadelia N, Hamer DH, Greer DM, Cervantes-Arslanian AM. Neurologic findings among inpatients with COVID-19 at a safety-net US hospital. Neurol Clin Prac 2021; 11(2): e83-e91. https://doi.org/10.1212/ CPJ.0000000000001031
11. Fleischer M, Köhrmann M, Dolff S, Szepanowski F, Schmidt K, Herbstreit F, et al. Observational cohort study of neurological involvement among patients with SARS-CoV-2 infection. Ther Adv Neurol Disord 2021; 26(14): 1756286421993701. h t t p s : / / d o i . org/10.1177/1756286421993701
12. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 77(6): 683-90. https://doi.org/10.1001/jamaneurol. 2020.1127
13. Ermis U, Rust MI, Bungenberg J, Costa A, Dreher M, Balfanz P, et al. Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients. Neurol Res Prac 2021; 3(1): 17. https://doi.org/10.1186/ s42466-021-00116-1
14. Chou SH, Beghi E, Helbok R, Moro E, Sampson J, Altamirano V, et al. GCS-NeuroCOVID Consortium and ENERGY Consortium. Global incidence of neurological manifestations among patients hospitalized with COVID- 19-A Report for the GCS-NeuroCOVID consortium and the ENERGY Consortium. JAMA Netw Open 2021; 4(5): e2112131.
15. Dhillon PS, Dineen RA, Morris H, Tanasescu R, Nikfekr E, Evans J, et al. Neurological disorders associated with COVID-19 hospital admissions: experience of a single tertiary healthcare center. Frontiers in Neurology 2021;
12: 640017. https://doi.org/10.3389/fneur.2021.640017 16. Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain J Neurol 2020; 143(10): 3104-20. https://doi. org/10.1093/brain/awaa240
17. Radmard S, Epstein SE, Roeder HJ, Michalak AJ, Shapiro SD, Boehme A, et al. Inpatient neurology consultations during the onset of the SARS-CoV-2 New York city pandemic: a single center case series. Frontiers in Neurology 2020; 11: 805. https://doi.org/10.3389/fneur.2020.00805
18. Alnefeesi Y, Siegel A, Lui LMW, Teopiz KM, Ho RCM, Lee Y, et al. Impact of SARS-CoV-2 infection on cognitive function: a systematic review. Frontiers in Psychiatry 2021; 11: 621773. https://doi.org/10.3389/fpsyt.2020.621773
19. Mazza MG, de Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, et al. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. Brain Behav Immun 2020; 89: 594-600. https://doi. org/10.1016/j.bbi.2020.07.037
20. COVID-19 Tanı ve Tedavisinde Kanıta Dayalı Öneriler ve Türk Toraks Derneği COVID-19 Görev Grubu Görüş Raporu, Türk Toraks Derneği COVID-19 E-Kitapları Serisi, 2021. ISBN: 978-605-06717-7-3
21. Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. ARC Study Group. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 2021; 76(4): 396-8. https://doi.org/10.1136/thoraxjnl- 2020-215818
22. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med 2021; 27(4): 626-31. https://doi.org/10.1038/ s41591-021-01292-y
23. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. Jama 2020; 323(13): 1239-42. https:// doi.org/10.1001/jama.2020.2648
24. Uygun O, Ertas M, Ekizoglu E, Bolay H, Ozge A, Kocasoy Orhan E, et al. Headache characteristics in COVID-19 pandemic-a survey study. J Headache Pain 2020; 21(1): 121. https://doi.org/10.1186/s10194-020-01188-1
25. Almeria M, Cejudo JC, Sotoca J, Deus J, Krupinski J. Cognitive profile following COVID-19 infection: clinical predictors leading to neuropsychological impairment. Brain Behav Immun Health 2020; 9: 100163. https://doi. org/10.1016/j.bbih.2020.100163
26. Woo MS, Malsy J, Pöttgen J, Seddiq Zai S, Ufer F, Hadjilaou A, et al. Frequent neurocognitive deficits after recovery from mild COVID-19. Brain Commun 2020 23; 2(2): fcaa205. https://doi.org/10.1093/braincomms/fcaa205
27. Bougakov D, Podell K, Goldberg E. Multiple Neuroinvasive Pathways in COVID-19. Molecular Neurobiol 2020; 58(2): 564-75. https://doi.org/10.1007/s12035-020- 02152-5
28. Yan CH, Faraji F, Prajapati DP, Ostrander BT, DeConde AS. Self‐reported olfactory loss associates with outpatient clinical course in COVID‐19. Int Forum Allergy Rhinol 2020; 10(7): 821-31. https://doi.org/10.1002/alr.22592
29. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol 2020; 84: 106504. https://doi. org/10.1016/j.intimp.2020.106504
30. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27(4): 601-15. https://doi. org/10.1038/s41591-021-01283-z
31. Santhosh L, Block B, Kim SY, Raju S, Shah RJ, Thakur N, et al. Rapid design and implementation of post-COVID-19 clinics. Chest 2021; 160(2): 671-7. https://doi. org/10.1016/j.chest.2021.03.044

APA	TASKIRAN SAG A, Eroglu E, Canlar S, POYRAZ B, Ozulken K, Mumcuoglu T, NUMANOĞLU N (2022). Subacute neurological sequelae in mild COVID-19 outpatients. , 27 - 36. 10.5578/tt.20229904
Chicago	TASKIRAN SAG Aslihan,Eroglu Erdal,Canlar Sule,POYRAZ BARIS MUSTAFA,Ozulken Kemal,Mumcuoglu Tarkan,NUMANOĞLU NUMAN Subacute neurological sequelae in mild COVID-19 outpatients. (2022): 27 - 36. 10.5578/tt.20229904
MLA	TASKIRAN SAG Aslihan,Eroglu Erdal,Canlar Sule,POYRAZ BARIS MUSTAFA,Ozulken Kemal,Mumcuoglu Tarkan,NUMANOĞLU NUMAN Subacute neurological sequelae in mild COVID-19 outpatients. , 2022, ss.27 - 36. 10.5578/tt.20229904
AMA	TASKIRAN SAG A,Eroglu E,Canlar S,POYRAZ B,Ozulken K,Mumcuoglu T,NUMANOĞLU N Subacute neurological sequelae in mild COVID-19 outpatients. . 2022; 27 - 36. 10.5578/tt.20229904
Vancouver	TASKIRAN SAG A,Eroglu E,Canlar S,POYRAZ B,Ozulken K,Mumcuoglu T,NUMANOĞLU N Subacute neurological sequelae in mild COVID-19 outpatients. . 2022; 27 - 36. 10.5578/tt.20229904
IEEE	TASKIRAN SAG A,Eroglu E,Canlar S,POYRAZ B,Ozulken K,Mumcuoglu T,NUMANOĞLU N "Subacute neurological sequelae in mild COVID-19 outpatients." , ss.27 - 36, 2022. 10.5578/tt.20229904
ISNAD	TASKIRAN SAG, Aslihan vd. "Subacute neurological sequelae in mild COVID-19 outpatients". (2022), 27-36. https://doi.org/10.5578/tt.20229904

APA	TASKIRAN SAG A, Eroglu E, Canlar S, POYRAZ B, Ozulken K, Mumcuoglu T, NUMANOĞLU N (2022). Subacute neurological sequelae in mild COVID-19 outpatients. Tüberküloz ve Toraks, 70(1), 27 - 36. 10.5578/tt.20229904
Chicago	TASKIRAN SAG Aslihan,Eroglu Erdal,Canlar Sule,POYRAZ BARIS MUSTAFA,Ozulken Kemal,Mumcuoglu Tarkan,NUMANOĞLU NUMAN Subacute neurological sequelae in mild COVID-19 outpatients. Tüberküloz ve Toraks 70, no.1 (2022): 27 - 36. 10.5578/tt.20229904
MLA	TASKIRAN SAG Aslihan,Eroglu Erdal,Canlar Sule,POYRAZ BARIS MUSTAFA,Ozulken Kemal,Mumcuoglu Tarkan,NUMANOĞLU NUMAN Subacute neurological sequelae in mild COVID-19 outpatients. Tüberküloz ve Toraks, vol.70, no.1, 2022, ss.27 - 36. 10.5578/tt.20229904
AMA	TASKIRAN SAG A,Eroglu E,Canlar S,POYRAZ B,Ozulken K,Mumcuoglu T,NUMANOĞLU N Subacute neurological sequelae in mild COVID-19 outpatients. Tüberküloz ve Toraks. 2022; 70(1): 27 - 36. 10.5578/tt.20229904
Vancouver	TASKIRAN SAG A,Eroglu E,Canlar S,POYRAZ B,Ozulken K,Mumcuoglu T,NUMANOĞLU N Subacute neurological sequelae in mild COVID-19 outpatients. Tüberküloz ve Toraks. 2022; 70(1): 27 - 36. 10.5578/tt.20229904
IEEE	TASKIRAN SAG A,Eroglu E,Canlar S,POYRAZ B,Ozulken K,Mumcuoglu T,NUMANOĞLU N "Subacute neurological sequelae in mild COVID-19 outpatients." Tüberküloz ve Toraks, 70, ss.27 - 36, 2022. 10.5578/tt.20229904
ISNAD	TASKIRAN SAG, Aslihan vd. "Subacute neurological sequelae in mild COVID-19 outpatients". Tüberküloz ve Toraks 70/1 (2022), 27-36. https://doi.org/10.5578/tt.20229904